Billiontoone (NASDAQ:BLLN) Price Target Raised to $135.00

Billiontoone (NASDAQ:BLLN) had its price objective increased by JPMorgan Chase & Co. from $130.00 to $135.00 in a research report released on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research analysts also recently commented on BLLN. BTIG Research reaffirmed a “buy” rating and issued a $130.00 price objective on shares of Billiontoone in a report on Thursday. Wall Street Zen cut shares of Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research upgraded Billiontoone from a “strong sell” rating to a “hold” rating in a research report on Friday, October 2nd. Weiss Ratings downgraded Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. Finally, Guggenheim raised their price target on Billiontoone from $125.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $126.88.

Billiontoone Price Performance

Shares of NASDAQ:BLLN opened at $113.94 on Thursday. The company has a quick ratio of 11.31, a current ratio of 11.25 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $5.38 billion and a PE ratio of 123.85. Billiontoone has a twelve month low of $61.96 and a twelve month high of $150.44. The company has a 50-day moving average price of $105.37 and a two-hundred day moving average price of $97.15.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. The firm had revenue of $109.45 million during the quarter. Billiontoone had a net margin of 10.95% and a return on equity of 9.16%. Equities analysts forecast that Billiontoone will post 0.88 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Oguzhan Atay sold 25,001 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $109.24, for a total value of $2,731,109.24. Following the transaction, the chief executive officer owned 16,667 shares of the company’s stock, valued at approximately $1,820,703.08. This represents a 60.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Bosch John Roderick Ten sold 2,834 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $113.17, for a total transaction of $320,723.78. Following the completion of the transaction, the senior vice president directly owned 16,551 shares in the company, valued at approximately $1,873,076.67. The trade was a 14.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 264,194 shares of company stock worth $27,797,333 in the last three months. 50.22% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Billiontoone

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC raised its stake in Billiontoone by 86.7% in the third quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $30,000 after purchasing an additional 130 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in Billiontoone during the second quarter valued at approximately $29,000. Toth Financial Advisory Corp lifted its position in Billiontoone by 60.0% during the third quarter. Toth Financial Advisory Corp now owns 800 shares of the company’s stock valued at $85,000 after purchasing an additional 300 shares during the last quarter. MCF Advisors LLC grew its stake in Billiontoone by 330.8% in the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after buying an additional 344 shares in the last quarter. Finally, Family Legacy Financial Solutions LLC purchased a new position in Billiontoone in the 3rd quarter worth approximately $53,000.

Key Stories Impacting Billiontoone

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results beat expectations: BillionToOne reported earnings of $0.32 per share versus a $0.16 consensus estimate, while revenue also topped analyst expectations. Q3 earnings report
• Positive Sentiment: Higher 2026 revenue outlook and upcoming product: The company raised its full-year revenue guidance to $460 million–$470 million and plans to launch Northstar Clear on December 15, giving investors signs of growth and a near-term product catalyst. Outlook and product launch
• Positive Sentiment: Analysts remain constructive: JPMorgan raised its price target from $130 to $135 and maintained an Overweight rating; BTIG reaffirmed its Buy rating with a $130 target. JPMorgan price-target change
• Negative Sentiment: Several executives sold shares: The CEO, CTO and an SVP disclosed sales, including a substantial reduction in the CTO’s reported holdings. The transactions were conducted under pre-arranged Rule 10b5-1 plans, which may temper concerns but could still weigh on sentiment. Insider sale report

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.